Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.



from The Medical News http://www.news-medical.net/news/20141229/Newron-Zambon-announce-re-submission-of-safinamide-NDA-to-FDA.aspx